Skip to main content
Top
Published in: Clinical Rheumatology 5/2008

01-05-2008 | Original Article

Analysis of the impact of fibromyalgia on quality of life: associated factors

Authors: Ma del Carmen Ubago Linares, Isabel Ruiz-Pérez, Ma José Bermejo Pérez, Antonio Olry de Labry-Lima, Elisa Hernández-Torres, Juncal Plazaola-Castaño

Published in: Clinical Rheumatology | Issue 5/2008

Login to get access

Abstract

We analysed the impact of fibromyalgia (FM) on the functional capacity of patients suffering this syndrome and identified factors that are associated with greater disease impact. We performed a cross-sectional descriptive telephone survey on all patients diagnosed with fibromyalgia during 2003 in a university hospital in Spain. Variables studied were socio-demographic, job, clinical, health and psycho-social characteristics of patients diagnosed with FM and impact of FM on them. Disease impact was measured by means of the Fibromyalgia Impact Questionnaire (FIQ). The rest of variables were collected by means of an expressly designed questionnaire. The relation between FIQ score and the other variables was performed with a bivariate analysis, using several tests depending on the variables involved. To analyse the factors associated with greatest disease impact, a multivariate linear regression model was designed. The average FIQ score for the sample was 63.6. Having a larger number of children, being tired and being in a depressed mood were the symptoms that most affected activities of daily living. A diagnosis of any mental illness, reference to repercussion on the family environment, a lower self-rated health and having consulted more specialists before FM diagnosis were associated with a higher impact after adjusting according to all the variables in the model. It can be confirmed that the FIQ is a useful instrument for measuring the impact of FM on quality of life. Identifying factors that determine the extent of its impact will enable more effective therapeutic strategies to be designed.
Footnotes
1
Mental illness is considered as any type of mental disorder (depression, anxiety, somatisation, phobias, etc.).
 
Literature
1.
go back to reference Wolfe F, Smythe HA, Yunnus MB et al (1990) The American College of Rheumatology (1990) criteria for the classification of fibromyalgia. Arthritis Rheum 33:160–172PubMedCrossRef Wolfe F, Smythe HA, Yunnus MB et al (1990) The American College of Rheumatology (1990) criteria for the classification of fibromyalgia. Arthritis Rheum 33:160–172PubMedCrossRef
2.
go back to reference WHO (1992) International statistical classification of diseases and related problems. ICD-10. WHO, Geneva WHO (1992) International statistical classification of diseases and related problems. ICD-10. WHO, Geneva
3.
go back to reference Wolfe F, Ross K, Anderson J et al (1995) The prevalence and characteristics of Fibromyalgia in the general population. Arthritis Rheum 38:19–28PubMedCrossRef Wolfe F, Ross K, Anderson J et al (1995) The prevalence and characteristics of Fibromyalgia in the general population. Arthritis Rheum 38:19–28PubMedCrossRef
4.
go back to reference White KP, Speechley M, Harth M et al (1999) The London Fibromyalgia Epidemiology Study: the prevalence of fibromyalgia syndrome in London, Ontario. J Rheumatol 26:1570–1576PubMed White KP, Speechley M, Harth M et al (1999) The London Fibromyalgia Epidemiology Study: the prevalence of fibromyalgia syndrome in London, Ontario. J Rheumatol 26:1570–1576PubMed
5.
go back to reference Ballina FJ, Martín P, Iglesias A et al (1995) La fibromialgia. Revisión clínica. Rev Clin Esp 195:326–331 Ballina FJ, Martín P, Iglesias A et al (1995) La fibromialgia. Revisión clínica. Rev Clin Esp 195:326–331
6.
go back to reference Mulero J (1997) Fibromialgia. Medicine 7:2682–2687 Mulero J (1997) Fibromialgia. Medicine 7:2682–2687
7.
go back to reference Valverde M, Juan A, Rivas B et al (2001) Fibromialgia. En: Estudio EPISER. Prevalencia e impacto de las enfermedades reumáticas en la población adulta española. Madrid: Msd y Sociedad Española de Reumatología 77–91 Valverde M, Juan A, Rivas B et al (2001) Fibromialgia. En: Estudio EPISER. Prevalencia e impacto de las enfermedades reumáticas en la población adulta española. Madrid: Msd y Sociedad Española de Reumatología 77–91
8.
go back to reference Ubago MC, Ruiz I, Bermejo MJ et al (2005) Características clínicas y psicosociales de personas con fibromialgia. Repercusión del diagnóstico sobre sus actividades. Rev Esp Salud Publica 79:683–695CrossRef Ubago MC, Ruiz I, Bermejo MJ et al (2005) Características clínicas y psicosociales de personas con fibromialgia. Repercusión del diagnóstico sobre sus actividades. Rev Esp Salud Publica 79:683–695CrossRef
9.
go back to reference Arnold LM, Keck PE, Welge JA (2000) Antidepressant treatment of fibromyalgia. A metaanalysis and review. Psychosomatics 41:104–13PubMedCrossRef Arnold LM, Keck PE, Welge JA (2000) Antidepressant treatment of fibromyalgia. A metaanalysis and review. Psychosomatics 41:104–13PubMedCrossRef
10.
go back to reference Fernández MA (2000) Fibromialgia. Rev Esp Reumatol 27:442–446 Fernández MA (2000) Fibromialgia. Rev Esp Reumatol 27:442–446
11.
go back to reference Schochat T, Beckmann C (2003) Sociodemographic characteristics, risk factors and reproduced history in subjets whith fibromyalgia. Results of a population based case-control study. Z Rheumatol 62:46–59PubMedCrossRef Schochat T, Beckmann C (2003) Sociodemographic characteristics, risk factors and reproduced history in subjets whith fibromyalgia. Results of a population based case-control study. Z Rheumatol 62:46–59PubMedCrossRef
12.
13.
go back to reference Wolfe F (1996) The fibromyalgia syndrome: a consensus report on fibromyalgia and disability. J Rheumatol 23:534–539PubMed Wolfe F (1996) The fibromyalgia syndrome: a consensus report on fibromyalgia and disability. J Rheumatol 23:534–539PubMed
14.
go back to reference Wolfe F (1997) The relation between tender points and fibromyalgia symptom variables: evidence that fibromyalgia is not a discrete disorder in the clinic. Ann Rheum Dis 56:268–271PubMed Wolfe F (1997) The relation between tender points and fibromyalgia symptom variables: evidence that fibromyalgia is not a discrete disorder in the clinic. Ann Rheum Dis 56:268–271PubMed
15.
16.
go back to reference Edwards, Bingham C III, Bathon et al (2006) Catastrophizing and pain in arthritis, fibromyalgia, and other rheumatic diseases. Arthritis Care Research 55:325–332PubMedCrossRef Edwards, Bingham C III, Bathon et al (2006) Catastrophizing and pain in arthritis, fibromyalgia, and other rheumatic diseases. Arthritis Care Research 55:325–332PubMedCrossRef
17.
go back to reference Okifuji A, Turk DC, Sherman JJ (2000) Evaluation of the relation-ship between depression and fibromyalgia syndrome: why aren’t all patients depressed? J Rheumatol 27:212–219PubMed Okifuji A, Turk DC, Sherman JJ (2000) Evaluation of the relation-ship between depression and fibromyalgia syndrome: why aren’t all patients depressed? J Rheumatol 27:212–219PubMed
18.
go back to reference Beth JM (2002) Does chronic pain predict future psychological distress? Pain 96:239–245CrossRef Beth JM (2002) Does chronic pain predict future psychological distress? Pain 96:239–245CrossRef
19.
go back to reference Suhr JA (2003) Neuropsychological impairment in fibromyalgia: relation to depression, fatigue and pain. J Psychosom Res 55:321–329PubMedCrossRef Suhr JA (2003) Neuropsychological impairment in fibromyalgia: relation to depression, fatigue and pain. J Psychosom Res 55:321–329PubMedCrossRef
20.
go back to reference Martínez E, González O, Crespo JM (2003) Fibromialgia: definición, aspectos clínicos, psicológicos, psiquiátricos y terapéuticos. Salud Mental 4:2–7 Martínez E, González O, Crespo JM (2003) Fibromialgia: definición, aspectos clínicos, psicológicos, psiquiátricos y terapéuticos. Salud Mental 4:2–7
21.
go back to reference Forseth KO, Husby G, Gran JT et al (1999) Prognostic Factors for the development of fibromyalgia in women with self-reported musculoskeletal pain. A prospective study. J Rheumatol 26:2458–2467PubMed Forseth KO, Husby G, Gran JT et al (1999) Prognostic Factors for the development of fibromyalgia in women with self-reported musculoskeletal pain. A prospective study. J Rheumatol 26:2458–2467PubMed
22.
go back to reference Rivera J, Alegre C, Ballina FJ et al (2006) Documento de consenso de la Sociedad Española de Reumatología sobre la fibromialgia. Reumatol Clin 2(Supl 1):S55–S66 Rivera J, Alegre C, Ballina FJ et al (2006) Documento de consenso de la Sociedad Española de Reumatología sobre la fibromialgia. Reumatol Clin 2(Supl 1):S55–S66
23.
go back to reference Ware JE, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473–483PubMedCrossRef Ware JE, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473–483PubMedCrossRef
24.
go back to reference Alonso J, Prieto L, Antó JM (1995) La versión española del SF-36 Health Survey (Cuestionario de salud SF-36): un instrumento para la medida de los resultados clínicos. Med Clin (Barc) 104:771–776 Alonso J, Prieto L, Antó JM (1995) La versión española del SF-36 Health Survey (Cuestionario de salud SF-36): un instrumento para la medida de los resultados clínicos. Med Clin (Barc) 104:771–776
25.
go back to reference Burckardt CS, Clark SR, Bennet RM (1991) The fibromyalgia impact questionnaire: development and validation. J Rheumatol 18:728–733 Burckardt CS, Clark SR, Bennet RM (1991) The fibromyalgia impact questionnaire: development and validation. J Rheumatol 18:728–733
26.
go back to reference Bennet R (2005) The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clin Exp Rheumatol 23(Suppl 39):154–162 Bennet R (2005) The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clin Exp Rheumatol 23(Suppl 39):154–162
27.
go back to reference Rivera J, González T (2004) The Fibromyalgia Impact Questionnaire: a validated Spanish version to assess the health status in women with fibromyalgia. Clin Exp Rheumatol 22:554–560PubMed Rivera J, González T (2004) The Fibromyalgia Impact Questionnaire: a validated Spanish version to assess the health status in women with fibromyalgia. Clin Exp Rheumatol 22:554–560PubMed
28.
go back to reference Esteve-Vives J, Batlle-gualda E, Reig A (1993) Spanish version of the health assessment questionnaire: reliability, validity and transcultural equivalency. Grupo para la adaptación del HAQ a la población española. J Rheumatol 20:2216–2222 Esteve-Vives J, Batlle-gualda E, Reig A (1993) Spanish version of the health assessment questionnaire: reliability, validity and transcultural equivalency. Grupo para la adaptación del HAQ a la población española. J Rheumatol 20:2216–2222
29.
go back to reference De Gracia M, Marco M, Ruiz J (2001) Evaluación de los aspectos psicológicos de la Fibromialgia. Anl Modif Conduct 21:959–980 De Gracia M, Marco M, Ruiz J (2001) Evaluación de los aspectos psicológicos de la Fibromialgia. Anl Modif Conduct 21:959–980
30.
go back to reference Boonen A, van den Heuvel R, van Tubergen A et al (2005) Large differences in cost-of-illness and well being between patients with fibromyalgia, chronic low back pain or ankylosing spondylitis. Ann Rheum Dis 64:396–402PubMedCrossRef Boonen A, van den Heuvel R, van Tubergen A et al (2005) Large differences in cost-of-illness and well being between patients with fibromyalgia, chronic low back pain or ankylosing spondylitis. Ann Rheum Dis 64:396–402PubMedCrossRef
31.
go back to reference Dönmez A, Zeki Karagülle M, Tercan N et al (2005) SPA therapy in fibromyalgia: a randomised controlled clinic study. Rheumatol Int 26:168–172PubMedCrossRef Dönmez A, Zeki Karagülle M, Tercan N et al (2005) SPA therapy in fibromyalgia: a randomised controlled clinic study. Rheumatol Int 26:168–172PubMedCrossRef
32.
go back to reference Fallon J, Bujak DI, Guardino S et al (1999) The Fibromyalgia Impact Questionnaire: a useful tool in evaluating patients with post-Lyme disease syndrome. Arthritis Care Res 12:42–47PubMedCrossRef Fallon J, Bujak DI, Guardino S et al (1999) The Fibromyalgia Impact Questionnaire: a useful tool in evaluating patients with post-Lyme disease syndrome. Arthritis Care Res 12:42–47PubMedCrossRef
33.
go back to reference White K, Speechley M, Harth M et al (1999) Comparing self-reported function and work disability in 100 community cases of fibromyalgia syndrome versus controls in London (Ontario). Arthritis Rheum 42:76–83PubMedCrossRef White K, Speechley M, Harth M et al (1999) Comparing self-reported function and work disability in 100 community cases of fibromyalgia syndrome versus controls in London (Ontario). Arthritis Rheum 42:76–83PubMedCrossRef
34.
go back to reference Gowans SE, Dehueck A, Voss S et al (2004) Six-month and one-year follow up of 23 weeks of aerobic exercise for individuals with fibromyalgia. Arthritis Rheum 51:890–898PubMedCrossRef Gowans SE, Dehueck A, Voss S et al (2004) Six-month and one-year follow up of 23 weeks of aerobic exercise for individuals with fibromyalgia. Arthritis Rheum 51:890–898PubMedCrossRef
35.
go back to reference Zijlstra TR, van de Laar MA, Bernelot HJ et al (2005) Spa treatment for primary fibromyalgia syndrome: a combination of thalassotherapy, exercise and patient education improves symptoms and quality of life. Rheumatology 44:539–546PubMedCrossRef Zijlstra TR, van de Laar MA, Bernelot HJ et al (2005) Spa treatment for primary fibromyalgia syndrome: a combination of thalassotherapy, exercise and patient education improves symptoms and quality of life. Rheumatology 44:539–546PubMedCrossRef
36.
go back to reference Yunus MB (1992) Plasma tryptophan and other amino acids in primary fibromyalgia: a controlled study. J Rheumatol 19:90–94PubMed Yunus MB (1992) Plasma tryptophan and other amino acids in primary fibromyalgia: a controlled study. J Rheumatol 19:90–94PubMed
37.
go back to reference Bazzichi L, Giannaccini G, Betti L et al (2006) Alteration of serotonin transporter density and activity in fibromyalgia. Arthritis Res Ther 8:99CrossRef Bazzichi L, Giannaccini G, Betti L et al (2006) Alteration of serotonin transporter density and activity in fibromyalgia. Arthritis Res Ther 8:99CrossRef
38.
go back to reference Birtane M, Uzunca K, Tastekin N et al (2007) The evaluation of quality of life in fibromyalgia syndrome: a comparison with rheumatoid arthritis by using SF-36 Health Survey. Clin Rheumatol 26:679–684PubMedCrossRef Birtane M, Uzunca K, Tastekin N et al (2007) The evaluation of quality of life in fibromyalgia syndrome: a comparison with rheumatoid arthritis by using SF-36 Health Survey. Clin Rheumatol 26:679–684PubMedCrossRef
39.
go back to reference Salomon L, Reeves W (2004) Factors influencing the diagnosis of chronic fatigue syndrome. Arch Intern Med 164:2241–2245CrossRef Salomon L, Reeves W (2004) Factors influencing the diagnosis of chronic fatigue syndrome. Arch Intern Med 164:2241–2245CrossRef
40.
go back to reference Martin DP, Sletten CD, Williams BA et al (2006) Improvement in fibromyalgia symptoms with acupuncture: results of a randomized controlled trial. Mayo Clin Proc 81:749–757PubMedCrossRef Martin DP, Sletten CD, Williams BA et al (2006) Improvement in fibromyalgia symptoms with acupuncture: results of a randomized controlled trial. Mayo Clin Proc 81:749–757PubMedCrossRef
41.
go back to reference Assis MR, Silva LE, Alves M et al (2006) A randomized controlled trial of deep water running: clinical effectiveness of aquatic exercise to treat fibromyalgia. Arthritis Rheum 55:57–65PubMedCrossRef Assis MR, Silva LE, Alves M et al (2006) A randomized controlled trial of deep water running: clinical effectiveness of aquatic exercise to treat fibromyalgia. Arthritis Rheum 55:57–65PubMedCrossRef
42.
go back to reference Culos-Reed S, Brawley L (2000) Fibromyalgia, physical activity, and daily functioning: the importance of efficacy and health-related quality of life. Arthritis Care Res 13:343–351PubMedCrossRef Culos-Reed S, Brawley L (2000) Fibromyalgia, physical activity, and daily functioning: the importance of efficacy and health-related quality of life. Arthritis Care Res 13:343–351PubMedCrossRef
43.
go back to reference Croft P (1994) Population study of tender points counts and pain as evidence of fibromyalgia. BMJ 309:696–699PubMed Croft P (1994) Population study of tender points counts and pain as evidence of fibromyalgia. BMJ 309:696–699PubMed
44.
go back to reference O’Malley P (2000) Treatment of fibromyalgia with antidepressants: a meta-analysis. J Gen Inter Medicine 15:659–666CrossRef O’Malley P (2000) Treatment of fibromyalgia with antidepressants: a meta-analysis. J Gen Inter Medicine 15:659–666CrossRef
Metadata
Title
Analysis of the impact of fibromyalgia on quality of life: associated factors
Authors
Ma del Carmen Ubago Linares
Isabel Ruiz-Pérez
Ma José Bermejo Pérez
Antonio Olry de Labry-Lima
Elisa Hernández-Torres
Juncal Plazaola-Castaño
Publication date
01-05-2008
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 5/2008
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-007-0756-1

Other articles of this Issue 5/2008

Clinical Rheumatology 5/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine